Hitting the Bullseye With Anti-BCMA Treatment: An In the Clinic Activity Evaluation (ID: i838-5) Survey

1.How many years have you been in practice?(Required.)

≥21

11-20

1-10

<1

2.How many patients with multiple myeloma do you manage per week?  (Required.)

1 to 10

11 to 25

26 to 50

I am not directly involved in patient care

3.After participating in this activity, how confident are you now in the management of patients with relapsed/refractory multiple myeloma (RRMM) in your practice?(Required.)

4.How committed are you to making changes in your practice based on your participation in this activity?  (Required.)

If not committed or do not plan to make changes, please indicate reason

5.Which of the following best describes the impact of this activity on your performance?(Required.)

I gained new strategies/skills/information I can apply to my area of practice

I need more information before I can change my practice

My practice is already consistent with the information presented

This activity will not change my practice

6.Which new strategies/skills/information will you apply to your area of practice? Please select all that apply.(Required.)

Increased ability to select anti-BCMA treatment for patients with RRMM

Increased familiarity with clinical trials of anti-BCMA agents

Increased familiarity with the adverse events associated with anti-BCMA therapies

Increased ability to manage adverse events associated with anti-BCMA therapies

Increased ability to implement multidisciplinary care strategies for patients receiving anti-BCMA therapy

7.What barriers do you see to making changes in your practice? Please select all that apply.(Required.)

Lack of knowledge regarding evidence-based strategies

Lack of convincing evidence to warrant change

Lack of time/resources to consider change

Insurance, reimbursement, or legal issues

Conflicting guidelines or evidence

Patient compliance and/or patient resource barriers

Other (please specify)

12.If you indicated that you perceived commercial bias or influence, please describe:

13.As a result of your participation in this activity, what is the one change you are most likely to implement in your practice?

14.Please list any clinical issues/problems within your scope of practice you would like to see addressed in future educational activities for multiple myeloma.